Hundreds of employers now include stem cell therapy in their insurance coverage, but is it worth the cost?

Now a 'necessity, not a luxury' for asset managers to reduce expenses.

The wild card that could impact the COLA in the immediate term is what one economist calls a 'trade conflagration.'

How can employee benefits administrators more effectively engage employees across generations in HSAs?